Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.26 USD
-0.06 (-2.72%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $2.26 0.00 (0.13%) 4:28 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for Cellectis SA falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 204 | 98 | 186 | 268 | 361 |
Receivables | 21 | 15 | 30 | 16 | 12 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 2 | 3 |
Other Current Assets | 8 | 31 | 10 | 30 | 16 |
Total Current Assets | 233 | 144 | 225 | 315 | 392 |
Net Property & Equipment | 55 | 64 | 79 | 72 | 24 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 2 | 2 | 1 |
Deposits & Other Assets | 8 | 9 | 7 | 7 | 6 |
Total Assets | 334 | 261 | 382 | 469 | 467 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 19 | 21 | 24 | 25 | 29 |
Current Portion Long-Term Debt | 5 | 5 | 2 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 122 | 29 | 15 | 21 | 32 |
Total Current Liabilities | 155 | 63 | 49 | 52 | 63 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 49 | 21 | 20 | 29 | 47 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 5 | 4 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 250 | 135 | 146 | 161 | 112 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 4 | 3 | 3 | 3 | 3 |
Capital Surplus | 523 | 583 | 935 | 864 | 843 |
Retained Earnings | -406 | -440 | -698 | -587 | -508 |
Other Equity | -37 | -21 | -3 | 29 | 18 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 85 | 126 | 236 | 309 | 355 |
Total Liabilities & Shareholder's Equity | 334 | 261 | 382 | 469 | 467 |
Total Common Equity | 85 | 126 | 236 | 309 | 355 |
Shares Outstanding | 55.50 | 45.60 | 45.40 | 42.40 | 42.40 |
Book Value Per Share | 1.53 | 2.76 | 5.21 | 7.28 | 8.38 |
Fiscal Year End for Cellectis SA falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 273 | 213 | 204 | 67 | 86 |
Receivables | 25 | 39 | 21 | 21 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 6 | 8 | 8 | 8 |
Total Current Assets | 306 | 258 | 233 | 96 | 113 |
Net Property & Equipment | 50 | 52 | 55 | 57 | 59 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 1 | 1 | 1 |
Deposits & Other Assets | 17 | 8 | 8 | 17 | 13 |
Total Assets | 407 | 354 | 334 | 210 | 228 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 16 | 19 | 20 | 19 |
Current Portion Long-Term Debt | 5 | 5 | 5 | 5 | 5 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 128 | 129 | 122 | 10 | 9 |
Total Current Liabilities | 160 | 158 | 155 | 44 | 42 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 58 | 63 | 49 | 43 | 46 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 3 | 43 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 259 | 264 | 250 | 134 | 131 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 6 | 4 | 4 | 3 | 3 |
Capital Surplus | 606 | 524 | 523 | 473 | 476 |
Retained Earnings | -425 | -400 | -406 | -363 | -346 |
Other Equity | -38 | -37 | -37 | -38 | -37 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 149 | 91 | 85 | 76 | 97 |
Total Liabilities & Shareholder's Equity | 407 | 354 | 334 | 210 | 228 |
Total Common Equity | 149 | 91 | 85 | 76 | 97 |
Shares Outstanding | 55.50 | 55.50 | 55.50 | 55.50 | 55.50 |
Book Value Per Share | 2.68 | 1.63 | 1.53 | 1.37 | 1.74 |